Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the 12 Small Cap Stocks with High Upside Potential. On June 17, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) reported positive topline data from its Phase 2 Explore-CKD trial of lorundrostat.

The company achieved positive topline data for the ongoing trials of lorundrostat for the treatment of subjects with hypertension and comorbid CKD. The crossover trial met the primary endpoint and showed clinically meaningful reductions in both systolic automated office blood pressure (AOBP) and urine albumin-to-creatinine ratio (UACR). The 25 mg dosage of lorundrostat achieved a 9.3 mmHg reduction in AOBP and a 7.5 mmHg placebo-adjusted reduction at four weeks. Whereas, lorundrostat showed a reduction in pre-defined endpoint spot urine UACR of 31%.

“Explore-CKD established that lorundrostat 25 mg once daily has a favorable clinical profile for this patient population. Along with the successful pivotal trials, Launch-HTN and Advance-HTN, and the ongoing open-label extension trial, these results comprise the core package for our planned NDA submission,” stated Jon Congleton, Chief Executive Officer of Mineralys.

The company continues to enroll subjects with OSA and uncontrolled hypertension for its ongoing Explore-OSA trials.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone in the U.S.

While we acknowledge the potential of MLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.